文献速递银屑病与炎症性皮肤病

Ixekizumab治疗中重度斑块状银屑病108周疗效与安全性:UNCOVER-3随机对照3期试验结果

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
PubMed 文献 · J Am Acad Dermatol · 2017-09-13

UNCOVER-3试验纳入1346例中重度斑块状银屑病患者,随机分配至不同剂量Ixekizumab、依那西普或安慰剂组,12周后进入长期延伸期。推荐剂量组(N=385)108周时PASI≥75应答率(as-observed)为93.4%,sPGA 0/1应答率为82.6%;长期延伸期84.5%患者报告至少1例治疗中出现的不良事件,多数为轻中度。结论认为Ixekizumab耐受良好且疗效持续至108周。

要点

  • 推荐剂量组108周PASI≥75应答率(as-observed)达93.4%。
  • 推荐剂量组108周sPGA 0/1应答率(as-observed)达82.6%。
  • 长期延伸期84.5%患者报告至少1例TEAE,多属轻中度。

核心结论

  • Ixekizumab耐受良好,并显示持续至108周的疗效。

研究设计与样本

  • UNCOVER-3为随机、对照3期临床试验,共纳入1346例中重度斑块状银屑病患者。
  • 患者按2:2:2:1随机分配至Ixekizumab每2周或每4周80mg、依那西普50mg每周两次或安慰剂组。
  • 第12周后患者转入长期延伸期,改为Ixekizumab每4周给药。

主要发现

  • 推荐剂量组(N=385)108周PASI≥75应答率:as-observed为93.4%,MI为88.3%,mMI为83.6%。
  • 推荐剂量组108周sPGA 0/1应答率:as-observed为82.6%,MI为78.3%,mMI为74.1%。
  • 长期延伸期1077例(84.5%)患者报告至少1例治疗中出现的不良事件,其中85%为轻中度。
  • 因不良事件停药的患者占6.4%。

临床怎么用

  • 对于中重度斑块状银屑病,Ixekizumab推荐剂量方案(0-12周每2周,长期延伸期每4周)可维持长期疗效。
  • 治疗期间需监测不良事件,多数为轻中度,因不良事件停药率较低。

局限性

  • 第12周后无对照治疗组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A, is efficacious in treating moderate-to-severe plaque psoriasis through 60 weeks. OBJECTIVE: To evaluate the efficacy and safety of ixekizumab through 108 weeks of treatment in UNCOVER-3. METHODS: Patients (N = 1346) were randomized 2:2:2:1 to 80 mg ixekizumab every 2 or 4 weeks, 50 mg etanercept twice weekly, or placebo. At week 12, patients switched to ixekizumab every 4 weeks during a long-term extension (LTE) period. Efficacy data were summarized using as-observed, multiple imputation (MI), and modified MI (mMI) methods. RESULTS: For patients (N = 385) receiving the recommended dose (ixekizumab every 2 weeks on weeks 0-12 and every 4 weeks during LTE), the 108-week as-observed, MI, and mMI response rates were 93.4%, 88.3%, and 83.6%, respectively, for patients achieving ≥75% improvement from baseline in the Psoriasis Area and Severity Index, and the 108-week as-observed, MI, and mMI response rates were 82.6%, 78.3%, and 74.1%, respectively, for patients with a static Physician's Global Assessment score of 0 or 1. During LTE, 1077 (84.5%) patients reported ≥1 treatment-emergent adverse event, and 85% were mild or moderate in severity. Discontinuation because of adverse events occurred in 6.4% of patients. LIMITATIONS: There was no comparison treatment group after week 12. CONCLUSION: Ixekizumab is well tolerated and demonstrates persistent efficacy through 108 weeks.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017. PMID: 28917383. doi:10.1016/j.jaad.2017.06.153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。